AstraZeneca's Prostate Cancer Treatment Trial Shows Clinically Meaningful Improvement
AstraZeneca (AZN): A Top Pick for Hedge Funds Due to Innovation and Rising Demand
Pfizer Meets Amyloidosis Rival as BridgeBio Wins FDA Nod for Attruby
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
European Equities Traded in the US as American Depositary Rise in Friday Trading, Up Over 1% for Week
Astrazeneca (AZN.US) and Amgen (AMGN.US) announced the domestic application for the subcutaneous injection of TSLP monoclonal antibody.
CDE's official website shows that astrazeneca (AZN.US) and amgen (AMGN.US) jointly submitted the marketing application for the TSLP monoclonal antibody Tezepelumab injection.